OXiGENE to Present Preclinical Data Demonstrating Antitumor Activity of ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model

company logo

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that data from a preclinical study of ZYBRESTAT® (fosbretabulin tromethamine/combretastatin A-4 phosphate or CA4P) demonstrating antitumor activity in a model of pancreatic neuroendocrine tumors (PNETs) will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held in the Hynes Convention Center, Boston, MA, October 19-23, 2013.

The data will be presented in a poster by ZiQiang Yuan, MD, Research Assistant Professor, Department of Surgery, Albert Einstein College of Medicine. Steven K. Libutti, MD, FACS, Professor of Surgery and Genetics, Albert Einstein College of Medicine, and Montefiore Medical Center, is the senior author.

Details on the OXiGENE poster presentation are as follows:

Title: Combretastatin A-4 Phosphate (CA4P) is effective for the treatment of functional pancreatic neuroendocrine tumors (PNETs) in a transgenic mouse model
Authors: ZiQiang Yuan1, Nikolas Zaphiros1, Asha Adem1, Norvilia Etienne1, Jai Balkissoon2, Dai Chaplin2, Steven K. Libutti1
1Albert Einstein College of Medicine, Bronx, NY; 2OXiGENE, South San Francisco, CA
Abstract: A4
Session ID/
Poster Session A; Angiogenesis and Antiangiogenesis Agents 1
Date & Time/
Sunday, October 20, 2013 12:30-3:00 pm, Exhibit Hall C-D

The abstract for this presentation can be viewed here:



OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. The Company's lead clinical product, ZYBRESTAT, is in development as a potential treatment for ovarian cancer and anaplastic thyroid cancer (ATC). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, and regulatory guidance relative to our clinical programs, achievement of our business and financing objectives, may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.

CONTACT: Investor and Media Contact: ir@oxigene.com 650-635-7000

Source:OXiGENE, Inc.